TY - JOUR
T1 - Protracted hypomobility in the absence of trigeminal sensitization after cortical spreading depolarization
T2 - Relevance to migraine postdrome
AU - Shibata, Mamoru
AU - Kitagawa, Satoshi
AU - Tang, Chunghua
AU - Unekawa, Miyuki
AU - Kayama, Yohei
AU - Shimizu, Toshihiko
AU - Nakahara, Jin
AU - Suzuki, Norihiro
N1 - Funding Information:
This study was supported by JSPS KAKENHI [grant number 19K07849 , to MS]; a grant from the Takeda Science Foundation to MS; and research grants from Pfizer Inc. [ WS1878886 ], Nippon Zoki Pharmaceutical Co., Ltd , and Kao Corporation to our research group. This work was supported in part by a Japan-China Sasakawa Medical Fellowship [grant number 2017816 ] and a State Scholarship Fund of the China Scholarship Council [grant number 201908500072 ] to CT.
Publisher Copyright:
© 2021 The Authors
PY - 2021/11
Y1 - 2021/11
N2 - Migraine sufferers often exhibit photophobia and physical hypoactivity in the postdrome and interictal periods, for which no effective therapy currently exists. Cortical spreading depolarization (CSD) is a neural phenomenon underlying migraine aura. We previously reported that CSD induced trigeminal sensitization, photophobia, and hypomobility at 24 h in mice. Here, we examined the effects of CSD induction on light sensitivity and physical activity in mice at 48 h and 72 h. Trigeminal sensitization was absent at both time points. CSD-subjected mice exhibited significantly less ambulatory time in both light (P = 0.0074, the Bonferroni test) and dark (P = 0.0354, the Bonferroni test) zones than sham-operated mice at 72 h. CSD-subjected mice also exhibited a significantly shorter ambulatory distance in the light zone at 72 h than sham-operated mice (P = 0.0151, the Bonferroni test). Neurotropin® is used for the management of chronic pain disorders, mainly in Asian countries. The CSD-induced reductions in ambulatory time and distance in the light zone at 72 h were reversed by Neurotropin® at 0.27 NU/kg. Our experimental model seems to recapitulate migraine-associated clinical features observed in the postdrome and interictal periods. Moreover, Neurotropin® may be effective in ameliorating postdromal/interictal hypoactivity, especially in a light environment.
AB - Migraine sufferers often exhibit photophobia and physical hypoactivity in the postdrome and interictal periods, for which no effective therapy currently exists. Cortical spreading depolarization (CSD) is a neural phenomenon underlying migraine aura. We previously reported that CSD induced trigeminal sensitization, photophobia, and hypomobility at 24 h in mice. Here, we examined the effects of CSD induction on light sensitivity and physical activity in mice at 48 h and 72 h. Trigeminal sensitization was absent at both time points. CSD-subjected mice exhibited significantly less ambulatory time in both light (P = 0.0074, the Bonferroni test) and dark (P = 0.0354, the Bonferroni test) zones than sham-operated mice at 72 h. CSD-subjected mice also exhibited a significantly shorter ambulatory distance in the light zone at 72 h than sham-operated mice (P = 0.0151, the Bonferroni test). Neurotropin® is used for the management of chronic pain disorders, mainly in Asian countries. The CSD-induced reductions in ambulatory time and distance in the light zone at 72 h were reversed by Neurotropin® at 0.27 NU/kg. Our experimental model seems to recapitulate migraine-associated clinical features observed in the postdrome and interictal periods. Moreover, Neurotropin® may be effective in ameliorating postdromal/interictal hypoactivity, especially in a light environment.
KW - Cortical spreading depolarization
KW - Migraine
KW - Migraine postdrome
KW - Neurotropin®
KW - Photophobia
KW - Physical activity
UR - http://www.scopus.com/inward/record.url?scp=85103737285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103737285&partnerID=8YFLogxK
U2 - 10.1016/j.neures.2021.03.010
DO - 10.1016/j.neures.2021.03.010
M3 - Article
C2 - 33819562
AN - SCOPUS:85103737285
SN - 0168-0102
VL - 172
SP - 80
EP - 86
JO - Neuroscience Research
JF - Neuroscience Research
ER -